Mucositis (transplant-related)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-03 — Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant: Early-phase trial evaluating hyperbaric oxygen therapy (HBOT) as a peri-transplant intervention in allogeneic PBSC transplant for CMML, CNL, myelofibrosis, and MDS/MPN overlap, with mucositis severity as one of the safety/efficacy endpoints alongside engraftment, neutrophil recovery, and GVHD outcomes. (novelty: 4)
Open questions
Related
Contributing findings
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
01-jul-2026
novelty 4
per-area 1
mentions
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
17-jun-2026
novelty 2
per-area 1
mentions
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
03-jun-2026
novelty 4
per-area 4
introduces